Treatment to prevent recurrent genital herpes

@article{Martinez2008TreatmentTP,
  title={Treatment to prevent recurrent genital herpes},
  author={Val{\'e}rie Martinez and Eric Caumes and Olivier Chosidow},
  journal={Current Opinion in Infectious Diseases},
  year={2008},
  volume={21},
  pages={42–48}
}
Purpose of review Genital herpes is the leading cause of genital ulcer disease worldwide and is among the most common sexually transmitted diseases. Recurrent genital herpes is associated with major medical and psychosocial morbidities; therefore, suppressive therapy is required, especially in patients with frequent and/or severe episodes. Recent findings A recent meta-analysis evaluated prophylactic regimens in immunocompetent hosts, and proposed four alternatives with similar efficacies… Expand
Newer trends in the management of genital herpes.
TLDR
Management of the sex partner, counseling and prevention advice are equally important in appropriate management of genital herpes, and Helicase-primase inhibitors, needle-free mucosal vaccine and a new microbicide product named VivaGel may become promising treatment options in the future. Expand
Chronic urticaria associated with recurrent genital herpes simplex infection and success of antiviral therapy--a report of two cases.
  • V. Zawar, K. Godse, S. Sankalecha
  • Medicine
  • International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • 2010
TLDR
Clinical and laboratory investigations for genital lesions supported a diagnosis of herpes simplex, and CIU, which was inadequately controlled with antihistamines alone, responded dramatically to the addition of acyclovir therapy. Expand
Herpes simplex virus infections, Pathophysiology and Management
TLDR
Recurrent outbreaks are common and vary between individuals; genetics play a role in the frequency of cold sore outbreaks. Expand
Long-term valacyclovir suppressive treatment after herpes simplex virus type 2 meningitis: a double-blind, randomized controlled trial.
TLDR
Suppressive treatment with 0.5 g of valacyclovir twice daily was not shown to prohibit recurrent meningitis and cannot be recommended for this purpose after HSVMeningitis in general. Expand
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
The treatment of inflammatory bowel disease (IBD) has been revolutionised over the past decade by the increasing use of immunomodulators, mainly azathioprine (AZA)/6-mercaptopurine (6-MP) andExpand
Health Care Seeking Among Men With Genital Ulcer Disease in South Africa: Correlates and Relationship to Human Immunodeficiency Virus-1 and Herpes Simplex Virus Type 2 Detection and Shedding
TLDR
Interventions to help shorten the duration between ulcer recognition and health care seeking for men with GUD are needed. Expand
Study of Seroprevalence of HSV Infection at Government General Hospital , Kakinada Dr .
Aims and Objectives: To study the seroprevalence of HSV infection in patients attending STI clinic, Government General Hospital, Kakinada and to note the association of HSV seropositivity with HIVExpand
Sexually transmitted infections in men.
TLDR
Screening for STIs should be part of all primary care practices, specifically targeting high-risk persons and those diagnosed with another STI. Expand
Women Facing HIV. Key Question on Women with HIV Infection: Italian Consensus Workshop
A panel of leading Italian specialists in infectious diseases, obstetrics and gynaecology met in a national consensus workshop on women facing HIV to review critical aspects and discussExpand
Neurovirulence et latence des virus Herpes simplex mutants
TLDR
It is shown that virulence properties of drugresistant HSV mutants could be predicted by their in vitro replication kinetics, as well as the neurovirulence properties and ability to establish latency of four clinical1llutants derived from HIV patients who failed acyclovir and/or foscamet therapy. Expand
...
1
2
...

References

SHOWING 1-10 OF 100 REFERENCES
Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group.
TLDR
Oral famciclovir (125 mg or 250mg 3 times daily or 250 mg twice daily) is an effective, well-tolerated treatment for the suppression of genital HSV infection in patients with frequent recurrences. Expand
A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks.
TLDR
The results of this first meta-analysis confirmed the high clinical efficacy of oral acyclovir, VACV, or famciclovir for prophylaxis against recurrent genital herpes. Expand
Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group.
TLDR
It is demonstrated that once daily valaciclovir (500 mg), is highly effective and well tolerated for the suppression of recurrent genital HSV infection. Expand
Once-daily valacyclovir to reduce the risk of transmission of genital herpes*
TLDR
Once-daily suppressive therapy with valacyclovir significantly reduces the risk of transmission of genital herpes among heterosexual, HSV-2-discordant couples. Expand
Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group.
TLDR
Valaciclovir is highly effective and well tolerated for suppression of recurrent genital herpes and once-daily regimens offer a useful option for patients who require suppressive therapy for management of genital herpes. Expand
Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group.
TLDR
Oral famciclovir, 250 mg, given twice daily for 4 months is an effective, well-tolerated treatment for the suppression of genital herpes in women with frequent recurrences, but single daily doses produced less complete suppression of herpes. Expand
Acyclovir suppression to prevent recurrent genital herpes at delivery.
TLDR
Suppressive acyclovir therapy significantly decreased the incidence of clinical genital herpes and the overall incidence of HSV excretion at delivery in patients with previous herpes infection. Expand
Suppression of recurrent genital herpes by single daily dosages of acyclovir.
TLDR
The 800-mg acyclovir tablet given daily was well-tolerated and effective for two years in the management of recurrent genital herpes and remained consistent throughout the study. Expand
Topical microbicides for the prevention of genital herpes infection.
TLDR
There is an urgent need for novel prophylactic methods, such as topical microbicides designed for genital application, to prevent both HSV and HIV transmission. Expand
Oral Famciclovir for Suppression of Recurrent Genital Herpes Simplex Virus Infection in Women: A Multicenter, Double-Blind, Placebo-Controlled Trial
TLDR
Oral famciclovir, 250 mg, given twice daily for 4 months is an effective, well-tolerated treatment for the suppression of genital herpes in women with frequent recurrences, but single daily doses produced less complete suppression of herpes. Expand
...
1
2
3
4
5
...